Retatrutide calculators

A 10 mg retatrutide vial mixed with 2 mL water gives 5 mg/mL — the same concentration as a 10 mg tirzepatide vial. The 2 mg illustrative dose drawn from that vial is exactly 40 units on a U-100 syringe. Repeatable across weeks, and easy to verify before each draw.

One Retatrutide-specific failure mode worth knowing before you use the reconstitution math: Letting reconstituted retatrutide warm to room temperature for extended periods on travel days. How does retatrutide's mechanism differ from semaglutide's mechanism? The primary difference is the number of hormone receptors they target. Semaglutide is a single agonist, designed to activate only the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide is a triple agonist, engineered to concurrently activate the GLP-1 receptor, the GIP receptor, and the glucagon receptor.

Vial size, diluent volume, and dose are the three inputs that genuinely change the answer. Doses-per-vial is a derived output — it's the vial mg divided by the dose mg, rounded down. The most common edge case is a tiny dose: at very high concentration, a 0.1 mL draw is only a few units on the syringe, which is hard to read accurately. If your unit count drops below five, consider reconstituting the next vial with more BAC water so each dose covers a larger volume.

The illustrative example on this page assumes a 10 mg vial reconstituted with 2 mL of bacteriostatic water. That produces a concentration of 5 mg per mL, which makes a 2 mg illustrative dose exactly 0.4 mL — 40 units on a U-100 syringe.

Larger vials of retatrutide benefit from larger diluent volumes for the same reason any peptide does: per-dose draws land on cleaner, easier-to-read unit counts on the syringe. A 20 mg vial reconstituted with 4 mL of bacteriostatic water gives the same per-dose unit count as a 10 mg vial with 2 mL, just over twice as many total doses.

The larger dose magnitudes studied in retatrutide trials introduce practical considerations for reconstitution and administration volume. Higher doses, such as the 8 mg or 12 mg levels observed in trial publications, require careful planning to manage the volume drawn for injection. For instance, using a standard reconstitution of a 10 mg vial with 2 mL of bacteriostatic water results in a concentration of 5 mg/mL. At this concentration, drawing a 12 mg dose would require a volume of 2.4 mL. This volume exceeds the capacity of a standard 1 mL U-100 insulin syringe and would necessitate either multiple separate injections or the use of a larger syringe, such as a 3 mL syringe, for a single administration. Planning reconstitution concentration with the final target dose in mind is critical for managing injection logistics.